Ligand Pharmaceuticals Inc (LGND) Institutional Ownership

Ownership Summary

Ligand Pharmaceuticals Inc (NASDAQ:LGND) has 350 institutional investors that have filed 13F reports for the period ending March 2026.

• Their combined ownership stood at 109.5% of outstanding shares in March 2026, up from 109.0% in December 2025.
• They increased total shares held in Ligand Pharmaceuticals by 15.43% from the prior quarter, while the number of investors in LGND increased 34.62% year over year.
• During the quarter, 193 of these 350 funds increased positions in LGND, 111 reduced exposure, and 46 held steady.
• Combined, these investors held 21.78Mn shares in LGND for March 2026, up by 2.91Mn shares quarter on quarter, and up 1.54Mn shares year over year.
• As of March 31, 2026, BlackRock, Inc. held the largest stake in Ligand Pharmaceuticals with 2.96Mn shares, accounting for 14.9% of total shares outstanding.
• The largest buyers of Ligand Pharmaceuticals for the quarter ending March 2026 were VANGUARD PORTFOLIO MANAGEMENT LLC (1.1Mn), Janus Henderson Group Plc (1.02Mn), VANGUARD CAPITAL MANAGEMENT LLC (848.09K), Invesco Ltd. (307.14K), VANGUARD FIDUCIARY TRUST CO (127.9K).
• The biggest sellers of Ligand Pharmaceuticals for the quarter ending March 2026 included Goldman Sachs Group Inc (476.9K), UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC (150.7K), NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO (146.3K), JACOBS LEVY EQUITY MANAGEMENT, INC (106.22K), MASSACHUSETTS FINANCIAL SERVICES CO /MA/ (95.48K).
• Ligand Pharmaceuticals's 10 largest shareholders as of March 2026 include BlackRock, Inc. (2.96Mn), Janus Henderson Group Plc (2.02Mn), VANGUARD PORTFOLIO MANAGEMENT LLC (1.1Mn), VANGUARD CAPITAL MANAGEMENT LLC (848.09K), Invesco Ltd. (823.6K), State Street Corp (778.86K), FMR LLC (596.13K), NOMURA ASSET MANAGEMENT INTERNATIONAL INC. (573.31K), Franklin Resources Inc (573.18K), Chicago Capital, LLC (561.68K) per Business Quant data.